Study Identifies Ideal Ixazomib Triplet Regimen for Newly Diagnosed Multiple Myeloma

Ixazomib plus cyclophosphamide, and dexamethasone elicited higher rates of efficacy compared with ixazomib/dexamethasone, followed by single-agent ixazomib maintenance, in patients with transplant-ineligible newly diagnosed multiple myeloma/

Read the full article here

Related Articles